Form 8-K - Current report:
SEC Accession No. 0001104659-20-134970
Filing Date
2020-12-14
Accepted
2020-12-14 06:05:01
Documents
7
Period of Report
2020-12-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2038391d1_8k.htm 8-K 26207
2 EXHIBIT 1.1 tm2038391d1_ex1-1.htm EX-1.1 78028
3 EXHIBIT 5.1 tm2038391d1_ex5-1.htm EX-5.1 10217
4 EXHIBIT 10.1 tm2038391d1_ex10-1.htm EX-10.1 224514
5 EXHIBIT 99.1 tm2038391d1_ex99-1.htm EX-99.1 8536
6 GRAPHIC tm2038391d1_ex1-1img001.jpg GRAPHIC 8415
7 GRAPHIC tm2038391d1_ex5-1img001.jpg GRAPHIC 4134
  Complete submission text file 0001104659-20-134970.txt   366578
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 201384995
SIC: 2834 Pharmaceutical Preparations